Oct. 25 at 5:24 PM
$BTAI BTAI has publicly indicated intent to start TRANQUILITY In-Care soon after the At-Home results and has been evaluating CROs to operationalize the trial. It hasn’t publicly announced “first patient dosed” or posted a new Phase 3 In-Care start on http://ClinicalTrials.gov yet.
Starting this trial will be a great step forward and positive results will be a game changer for Alzheimer’s and dementia patients. One report estimates the global Alzheimer’s agitation treatment market at ~ US
$4.5 billion in 2024, and projects growth to around US
$8.2 billion by 2033 (CAGR ~8 %) for that specific indication.
Canaccord Conference (Aug 12, 2025): “We have a protocol that [FDA] agreed on, ready to go… selecting a CRO… triggering the trial will be the next steps… basically ready to go very soon.”
HC Wainwright Conference (Sep 8, 2025): They had “agreement… for the Alzheimer’s program,” with CRO evaluations underway to initiate the trial.
